Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.
2.

Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project.

Black S, Shinefield H, Ray P, Lewis E, Chen R, Glasser J, Hadler S, Hardy J, Rhodes P, Swint E, Davis R, Thompson R, Mullooly J, Marcy M, Vadheim C, Ward J, Rastogi S, Wise R.

Pediatr Infect Dis J. 1997 May;16(5):500-3.

PMID:
9154545
3.
4.

Re: "Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design".

Farrington CP.

Am J Epidemiol. 2004 Apr 1;159(7):717-8; author reply 718-20. No abstract available.

PMID:
15033652
5.

Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain.

da Cunha SS, Rodrigues LC, Barreto ML, Dourado I.

Vaccine. 2002 Jan 15;20(7-8):1106-12.

PMID:
11803071
6.

Surveillance of measles-mumps-rubella vaccine-associated aseptic meningitis in Germany.

Schlipköter U, Mühlberger N, von Kries R, Weil J.

Infection. 2002 Dec;30(6):351-5.

PMID:
12478324
8.

Neurologic disorders after measles-mumps-rubella vaccination.

Mäkelä A, Nuorti JP, Peltola H.

Pediatrics. 2002 Nov;110(5):957-63.

PMID:
12415036
9.

No demonstrable association between the Leningrad-Zagreb mumps vaccine strain and aseptic meningitis in a large clinical trial in Egypt.

Sharma HJ, Oun SA, Bakr SS, Kapre SV, Jadhav SS, Dhere RM, Bhardwaj S.

Clin Microbiol Infect. 2010 Apr;16(4):347-52. doi: 10.1111/j.1469-0691.2010.03121.x.

10.

Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs.

Dourado I, Cunha S, Teixeira MG, Farrington CP, Melo A, Lucena R, Barreto ML.

Am J Epidemiol. 2000 Mar 1;151(5):524-30.

PMID:
10707922
11.

Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.

Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B.

Am J Epidemiol. 2007 Mar 15;165(6):704-9.

PMID:
17204517
12.

Safety evaluation of MMR vaccine during a primary school campaign in Saudi Arabia.

Al-Mazrou Y, Tumsah S, Khalil M, Al-Jeffri M, Afzal MA, al-Ghamdy Y, Mishkhas A, Essa M.

J Trop Pediatr. 2002 Dec;48(6):354-8.

PMID:
12521278
13.

Aseptic meningitis after measles-mumps-rubella (MMR) vaccination.

Mamishi S, Sarkardeh M, Pourakbari B, Keshavarz Valian S, Sabouni F, Mahmoudi S.

Br J Biomed Sci. 2016;73(2):84-6. doi: 10.1080/09674845.2016.1159047. No abstract available.

PMID:
27181175
14.

Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination.

Virtanen M, Peltola H, Paunio M, Heinonen OP.

Pediatrics. 2000 Nov;106(5):E62.

PMID:
11061799
15.

Statistical assessment of the association between vaccination and rare adverse events post-licensure.

Andrews NJ.

Vaccine. 2001 Oct 15;20 Suppl 1:S49-53; discussion S45-8.

PMID:
11587812
16.

Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up.

Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H.

Pediatr Infect Dis J. 2000 Dec;19(12):1127-34.

PMID:
11144371
18.

Estimation of the risk of aseptic meningitis associated with mumps vaccination, France, 1991-1993.

Rebiere I, Galy-Eyraud C.

Int J Epidemiol. 1995 Dec;24(6):1223-7.

PMID:
8824866
20.

Effect of gender on reporting of MMR adverse events in Saudi Arabia.

Khalil MK, Al-Mazrou YY, Al-Ghamdi YS, Tumsah S, Al-Jeffri M, Meshkhas A.

East Mediterr Health J. 2003 Jan-Mar;9(1-2):152-8.

PMID:
15562745
Items per page

Supplemental Content

Support Center